Impacto de enfermedades foliares del trigo en la fertilidad de la espiga

El objetivo del trabajo fue analizar el impacto de las enfermedades foliares de trigo sobre el coeficiente de fertilidad de la espiga (CFE) en una amplia colección de genotipos de trigo y evaluar su posible asociación negativa con el peso de mil granos (PMG). Se realizó un ensayo en la Estación Experimental Julio Hirschhorn con diseño de parcela dividida, siendo la parcela principal los tratamientos con y sin fungicida y la subparcela 102 genotipos de trigo primaverales del banco de germoplasma German Federal ex situ Genebank con dos repeticiones. Se evaluó la severidad de las plantas de trigo en tres estadios (encañazón, floración, grano pastoso), el área bajo la curva de progreso de la enfermedad, el CFE (relación entre el número de granos.espiga-1 cosecha/peso seco espiga en antesis) y el PMG.Se encontraron diferencias significativas en la severidad entre los tratamientos de los diferentes fungicida, excepto en encañazón, entre los genotipos y en la interacción tratamiento de fungicida y los genotipo en todos los estadios. No hubo diferencias significativas para CFE entre tratamientos de fungicidas, pero si entre genotipos y para la interacción tratamiento de fungicida × genotipo. Además, se observó que algunos genotipos disminuyeron el CFE por efecto de la enfermedad y otros lo mantuvieron o hubo ligeros incrementos, siendo las medias para los genotipos sin tratamiento de fungicida de 56,87 y para los tratados con fungicida de 53,95. El PMG medio fue de 31,74 g para los no tratados con fungicida y de 38,95 g para los tratados. En cuanto al análisis de regresión entre el CFE y el PMG, mostró una relación ligeramente negativa y no significativo., indicando que hay genotipos que mantienen el PMG aún con altos CFE lo que resulta promisorio para planes de mejoramiento.Facultad de Ciencias Agrarias y Forestale

Metabolómica: una nueva herramienta para el estudio conjunto de la aterosclerosis y la estenosis aórtica degenerativa

Comunicaciones a congreso

Hacia un completo entendimiento de la fisiopatología del síndrome coronario agudo mediante la combinación de estudios proteómicos y metabolómicos

Comunicaciones a congreso

A genome-wide association study on liver stiffness changes during hepatitis c virus infection cure

Liver stiffness (LS) at sustained virological response (SVR) after direct-acting antivirals (DAA)-based therapy is a predictor of liver events in hepatitis C virus (HCV)-infected patients. The study aim was to identify genetic factors associated with LS changes from the moment of starting anti-HCV therapy to SVR. This prospective study included HCV-infected patients from the GEHEP 011 cohort who achieved SVR with DAA-based therapy, with LS pre-treatment ≥9.5 kPa and LS measurement available at SVR. Plink and Magma software were used to carry out genome-wide single-nucleotide polymorphism (SNP)-based and gene-based association analyses, respectively. The ShinyGO application was used for exploring enrichment in Gene Ontology (GO) categories for biological processes. Overall, 242 patients were included. Median (quartile 1, quartile 3) LS values at pre-treatment and at SVR were 16.8 (12, 28) kPa and 12.0 (8.5, 19.3) kPa, respectively. Thirty-five SNPs and three genes reached suggestive association with LS changes from the moment of starting anti HCV therapy to SVR. GO categories related to DNA packaging complex, DNA conformation change, chromosome organization and chromatin organization were significantly enriched. Our study reports possible genetic factors associated with LS changes during HCV-infection cure. In addition, our results suggest that processes related to DNA conformation are also involved in these changes

High Irisin levels in nondiabetic HIV-infected males are associated with insulin resistance, nonalcoholic fatty liver disease, and subclinical atherosclerosis

Objective: HIV infection is associated with an increased risk of cardiovascular disease. Irisin is a miokyne secreted by skeletal muscle, which may influence insulin homeostasis, nonalcoholic fatty liver disease (NAFLD) and atherosclerosis. Our objective was to evaluate the relationships between serum irisin, insulin homeostasis, NAFLD and subclinical atherosclerosis in HIV-infected males. Design: Cross-sectional study in a cohort of HIV-infected patients. Patients: Inclusion criteria: men older than 18 years; antiretroviral therapy (ART) -naïve or on effective ART (<50 HIV-1 RNA copies/mL) without changes in the previous 6 months; no diabetes or hepatitis C. Measurements: Irisin was measured by enzymatic immunoassay (Phoenix Pharmaceuticals), insulin sensitivity by homeostasis model assessment of insulin resistance (HOMA-IR), as well as the 2-hour continuous infusion of glucose with model assessment (CIGMA-HOMA). Hepatic steatosis was measured by 1-H magnetic resonance spectroscopy, subclinical atherosclerosis by evaluation of carotid intima-media thickness (C-IMT), measured by Ultrasonography. Results: Eight nine men (age 42.0 ± 8.3 years, duration of HIV infection 7.9 ± 5.6 years, CD4 count 547 ± 279 cells/mL) were included. Circulating irisin was positively related to HOMA-IR and CIGMA-HOMA, hepatic triglyceride content, and to VAT/SAT ratio. Higher irisin concentrations were associated with higher C-IMT, although this association did not persist in multivariate analysis. Lipodystrophy and a higher baseline PAI-1 concentration were independently associated with C-IMT. Conclusions: In male HIV patients without diabetes, higher irisin concentrations are positively associated with insulin resistance, NAFLD and subclinical atherosclerosis. However, waist-hip- ratio is the main determinant of insulin resistance, and PAI-1 and lipodystrophy were the strongest determinants of IMT in this population

Key Contributions by the Swiss Tropical and Public Health Institute Towards New and Better Drugs for Tropical Diseases

Thanks to its expertise in clinical research, epidemiology, infectious diseases, microbiology, parasitology, public health, translational research and tropical medicine, coupled with deeply rooted partnerships with institutions in low- and middle-income countries (LMICs), the Swiss Tropical and Public Health Institute (Swiss TPH) has been a key contributor in many drug research and development consortia involving academia, pharma and product development partnerships. Our know-how of the maintenance of parasites and their life-cycles in the laboratory, plus our strong ties to research centres and disease control programme managers in LMICs with access to field sites and laboratories, have enabled systems for drug efficacy testing in vitro and in vivo, clinical research, and modelling to support the experimental approaches. Thus, Swiss TPH has made fundamental contributions towards the development of new drugs – and the better use of old drugs – for neglected tropical diseases and infectious diseases of poverty, such as Buruli ulcer, Chagas disease, food-borne trematodiasis (e.g. clonorchiasis, fascioliasis and opisthorchiasis), human African trypanosomiasis, leishmaniasis, malaria, schistosomiasis, soil-transmitted helminthiasis and tuberculosis. In this article, we show case the success stories of molecules to which Swiss TPH has made a substantial contribution regarding their use as anti-infective compounds with the ultimate aim to improve people’s health and well-being

A Novel Multi‐Functional Thiophene‐Based Organic Cation as Passivation, Crystalline Orientation, and Organic Spacer Agent for Low‐Dimensional 3D/1D Perovskite Solar Cells

Recently, the mixed-dimensional (3D/2D or 3D/1D) perovskite solar cells using small organic spacers have attracted interest due to their outstanding long-term stability. Here, a new type of thiophene-based organic cation 2-(thiophene-2yl-)pyridine-1-ium iodide (ThPyI), which is used to fabricate mixed-dimensional 3D/1D perovskite solar cells, is presented. The ThPyI-based 1D perovskitoid is applied as a passivator on top of a 3D methyl ammonium lead iodide (MAPI) to fabricate surface-passivated 3D/1D perovskite films or added alone into the 3D perovskite precursor to generate bulk-passivated 3D MAPI. The 1D perovskitoid acts as a passivating agent at the grain boundaries of surface-passivated 3D/1D, which improves the power conversion efficiency (PCE) of the solar cells. Grazing incidence wide-angle X-ray scattering (GIWAXS) studies confirm that ThPyI triggers the preferential orientation of the bulk MAPI slabs, which is essential to enhance charge transport. Champion bulk-passivated 3D and surface-passivated 3D/1D devices yield 14.10% and 19.60% PCE, respectively. The bulk-passivated 3D offers favorable stability, with 84% PCE retained after 2000 h without encapsulation. This study brings a new perspective to the design of organic spacers having a different binding motif and a passivation strategy to mitigate the impact of defects in hybrid 3D/1D perovskite solar cells

Impact of influenza related hospitalization in Spain: characteristics and risk factor of mortality during five influenza seasons (2016 to 2021)

BackgroundEstimating the global influenza burden in terms of hospitalization and death is important for optimizing prevention policies. Identifying risk factors for mortality allows for the design of strategies tailored to groups at the highest risk. This study aims to (a) describe the clinical characteristics of hospitalizations with a diagnosis of influenza over five flu seasons (2016–2017 to 2020–2021), (b) assess the associated morbidity (hospitalization rates and ICU admissions rate), mortality and cost of influenza hospitalizations in different age groups and (c) analyze the risk factors for mortality.MethodsThis retrospective study included all hospital admissions with a diagnosis of influenza in Spain for five influenza seasons. Data were extracted from the Spanish National Surveillance System for Hospital Data from 1 July 2016 to 30 June 2021. We identified cases coded as having influenza as a primary or secondary diagnosis (International Classification of Diseases, 10th revision, J09-J11). The hospitalization rate was calculated relative to the general population. Independent predictors of mortality were identified using multivariable logistic regression.ResultsOver the five seasons, there were 127,160 hospitalizations with a diagnosis of influenza. The mean influenza hospitalization rate varied from 5/100,000 in 2020–2021 (COVID-19 pandemic) to 92.9/100,000 in 2017–2018. The proportion of influenza hospitalizations with ICU admission was 7.4% and was highest in people aged 40–59 years (13.9%). The case fatality rate was 5.8% overall and 9.4% in those aged 80 years or older. Median length of stay was 5 days (and 6 days in the oldest age group). In the multivariable analysis, independent risk factors for mortality were male sex (odds ratio [OR] 1.14, 95% confidence interval [95% CI] 1.08–1.20), age (&lt;5 years: OR 1; 5–19 years: OR 2.02, 95%CI 1.17–3.49; 20–39 years: OR 4.11, 95% CI 2.67–6.32; 40–59 years: OR 8.15, 95% CI 5.60–11.87; 60–79 years: OR 15.10, 95% CI 10.44–21.84; ≥80 years: OR 33.41, 95% CI 23.10–48.34), neurological disorder (OR 1.97, 95% CI 1.83–2.11), heart failure (OR 1.85, 95% CI 1.74–1.96), chronic kidney disease (OR 1.33, 95% CI 1.25–1.41), chronic liver disease (OR 2.95, 95% CI 2.68–3.27), cancer (OR 1.85, 95% CI 1.48–2.24), coinfection with SARS-CoV2 (OR 3.17, 95% CI 2.34–4.28), influenza pneumonia (OR 1.76, 95% CI 1.66–1.86) and admission to intensive care (OR 7.81, 95% CI 7.31–8.36).ConclusionInfluenza entails a major public health burden. People aged over 60—and especially those over 80—show the longest hospital stays. Age is also the most significant risk factor for mortality, along with certain associated comorbidities

In Vitro Antifungal Activity of Ibrexafungerp (SCY-078) Against Contemporary Blood Isolates From Medically Relevant Species of Candida: A European Study

BackgroundIbrexafungerp (SCY-078) is the newest oral and intravenous antifungal drug with broad activity, currently undergoing clinical trials for invasive candidiasis. ObjectiveThe aim of this study was to assess the in vitro activity of ibrexafungerp and comparators against a collection of 434 European blood isolates of Candida. MethodsIbrexafungerp, caspofungin, fluconazole, and micafungin minimum inhibitory concentrations (MICs) were collected from 12 European laboratories for 434 blood isolates, including 163 Candida albicans, 108 Candida parapsilosis, 60 Candida glabrata, 40 Candida tropicalis, 29 Candida krusei, 20 Candida orthopsilosis, 6 Candida guilliermondii, 2 Candida famata, 2 Candida lusitaniae, and 1 isolate each of Candida bracarensis, Candida catenulata, Candida dubliniensis, and Candida kefyr. MICs were determined by the EUCAST broth microdilution method, and isolates were classified according to recommended clinical breakpoints and epidemiological cutoffs. Additionally, 22 Candida auris from different clinical specimens were evaluated. ResultsIbrexafungerp MICs ranged from 0.016 to >= 8 mg/L. The lowest ibrexafungerp MICs were observed for C. albicans (geometric MIC 0.062 mg/L, MIC range 0.016-0.5 mg/L) and the highest ibrexafungerp MICs were observed for C. tropicalis (geometric MIC 0.517 mg/L, MIC range 0.06->= 8 mg/L). Modal MICs/MIC(50)s (mg/L) against Candida spp. were 0.125/0.06 for C. albicans, 0.5/0.5 for C. parapsilosis, 0.25/0.25 for C. glabrata, 0.5/0.5 for C. tropicalis, 1/1 for C. krusei, 4/2 for C. orthopsilosis, and 0.5/0.5 for C. auris. Ibrexafungerp showed activity against fluconazole- and echinocandin-resistant isolates. If adopting wild-type upper limits, a non-wild-type phenotype for ibrexafungerp was only observed for 16/434 (3.7%) isolates: 11 (4.6%) C. parapsilosis, 4 (5%) C. glabrata, and 1 (2.5%) C. tropicalis. ConclusionIbrexafungerp showed a potent in vitro activity against Candida.This study received funding from SCYNEXIS. The funder was not involved in the study design, collection, analysis, interpretation of data, the writing of the article, or the decision to submit it for publication. CM-A is a recipient of a grant from Fundació n ONCE (Oportunidad al Talento). EE, AG, NJ, CM-A, and GQ have received grant support from Consejerı́a de Educación, Universidades e Investigación del Gobierno Vasco (GIC15 IT-990-16), Fondo de Investigación Sanitaria del Gobierno de España (FIS PI11/00203), and UPV/EHU (UFI 11/25). All authors declare no other competing interests